Cassava Sciences, Inc. (NASDAQ:SAVA - Get Free Report) insider Robert Christopher Cook bought 13,725 shares of the company's stock in a transaction dated Tuesday, September 30th. The stock was bought at an average cost of $2.91 per share, for a total transaction of $39,939.75. Following the acquisition, the insider owned 13,725 shares of the company's stock, valued at approximately $39,939.75. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Cassava Sciences Stock Up 7.2%
Shares of NASDAQ SAVA traded up $0.23 during mid-day trading on Thursday, hitting $3.43. 2,928,940 shares of the company were exchanged, compared to its average volume of 1,727,830. The stock has a 50 day simple moving average of $2.36 and a 200-day simple moving average of $2.06. Cassava Sciences, Inc. has a 1-year low of $1.15 and a 1-year high of $33.98. The firm has a market cap of $165.70 million, a price-to-earnings ratio of -1.35 and a beta of -0.98.
Cassava Sciences (NASDAQ:SAVA - Get Free Report) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.18) EPS for the quarter. Analysts anticipate that Cassava Sciences, Inc. will post -3.97 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Cassava Sciences
Several institutional investors and hedge funds have recently added to or reduced their stakes in SAVA. TT Capital Management LLC acquired a new stake in shares of Cassava Sciences in the 2nd quarter valued at approximately $28,000. Aristides Capital LLC acquired a new stake in Cassava Sciences in the second quarter valued at $29,000. Ground Swell Capital LLC purchased a new stake in shares of Cassava Sciences during the 2nd quarter worth $31,000. Catalyst Funds Management Pty Ltd acquired a new position in Cassava Sciences during the second quarter worth about $34,000. Finally, Jump Financial LLC acquired a new stake in shares of Cassava Sciences during the 2nd quarter valued at approximately $50,000. Institutional investors and hedge funds own 38.05% of the company's stock.
About Cassava Sciences
(
Get Free Report)
Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cassava Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cassava Sciences wasn't on the list.
While Cassava Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
